Literature DB >> 2176544

Chromosome alterations in 21 non-small cell lung carcinomas.

I Miura1, J M Siegfried, J Resau, S M Keller, J Y Zhou, J R Testa.   

Abstract

Cytogenetic analysis was performed on 16 primary tumors, 2 effusions, and 3 cell lines from 21 patients with non-small cell lung cancer (NSCLC). In 20 patients specimens were obtained prior to initiating cytotoxic therapy. Extensive clonal chromosome alterations were found in all cases. The most frequent numerical changes were polysomy 7 and polysomy 20 (each seen in 12 specimens). In addition, tumor cells from another six cases exhibited partial trisomy 7, with the shortest region of overlap (SRO) at 7p11-p13. Rearrangements of chromosomes 1, 3, 6, 8, 11, 15, 17, and 19 were each observed in nine or more tumors. Breakpoints were clustered at several chromosomal sites, including 1p13, 3p13, 15p11-q11, 17p11, and 19q13. Recurrent loss involving 1p, 3p, 6q, 11p, 15p, 17p, and 19q were each seen in at least eight cases. The SRO of 3p losses was at band 3p21. Double minute chromosomes were found in three tumors. Overall, our findings indicate that even though karyotypes in newly diagnosed NSCLC are very complex, recurrent cytogenetic changes can be identified. The high incidence of loss of 17p (14 of 21 specimens) appears to be compatible with reports implicating the TP53 gene (at band 17p13) as a frequent site for genetic alteration in lung cancer. Moreover, the recurrence of loss of 3p (12 cases) and 11p (10 cases) is also consistent with recent molecular evidence. The existence of other "hot spots" for cytogenetic change, particularly those involving specific regions on chromosomes 7, 15, and 19, warrants further molecular investigation of these sites in NSCLC.

Entities:  

Mesh:

Year:  1990        PMID: 2176544     DOI: 10.1002/gcc.2870020411

Source DB:  PubMed          Journal:  Genes Chromosomes Cancer        ISSN: 1045-2257            Impact factor:   5.006


  7 in total

1.  Exfoliative cytologic evaluation of primary cultured lung carcinomas.

Authors:  J H Resau; C D Albright; J R Cottrell; K L Colombo-Burke; S C Aisner; I Miura; J R Testa
Journal:  Cytotechnology       Date:  1991-06       Impact factor: 2.058

Review 2.  The pathophysiology and management of spine metastasis from lung cancer.

Authors:  J S Greenberger
Journal:  J Neurooncol       Date:  1995       Impact factor: 4.130

3.  Combined classical cytogenetics and microarray-based genomic copy number analysis reveal frequent 3;5 rearrangements in clear cell renal cell carcinoma.

Authors:  Jianming Pei; Madelyn M Feder; Tahseen Al-Saleem; Zemin Liu; Angen Liu; Gary R Hudes; Robert G Uzzo; Joseph R Testa
Journal:  Genes Chromosomes Cancer       Date:  2010-07       Impact factor: 5.006

4.  AKT2, a putative oncogene encoding a member of a subfamily of protein-serine/threonine kinases, is amplified in human ovarian carcinomas.

Authors:  J Q Cheng; A K Godwin; A Bellacosa; T Taguchi; T F Franke; T C Hamilton; P N Tsichlis; J R Testa
Journal:  Proc Natl Acad Sci U S A       Date:  1992-10-01       Impact factor: 11.205

5.  The correlation between gain of chromosome 8q and survival in patients with clear and papillary renal cell carcinoma.

Authors:  Reza Mehrazin; Essel Dulaimi; Robert G Uzzo; Karthik Devarjan; Jianming Pei; Marc C Smaldone; Alexander Kutikov; Joseph R Testa; Tahseen Al-Saleem
Journal:  Ther Adv Urol       Date:  2017-10-31

6.  Interphase cytogenetics of lung tumors using in situ hybridization: numerical aberrations.

Authors:  S Y Kim; K J Lee; S C Hong; P S Han; J J Lee; H J Cho; A K Kim; J O Kim; M S Lee
Journal:  Korean J Intern Med       Date:  1994-07       Impact factor: 2.884

7.  Allelic imbalance in 1p, 7q, 9p, 11p, 12q and 16q regions in non-small cell lung carcinoma and its clinical association: a pilot study.

Authors:  Karolina H Czarnecka; Monika Migdalska-Sęk; Adam Antczak; Dorota Pastuszak-Lewandoska; Jacek Kordiak; Ewa Nawrot; Daria Domańska; Dorota Kaleta; Paweł Górski; Ewa Barbara Brzeziańska
Journal:  Mol Biol Rep       Date:  2013-10-04       Impact factor: 2.316

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.